NCT04594850 (Cellgram-ED) is a Phase 2 clinical trial of Cellgram-ED in Erectile Dysfunction, sponsored by Pharmicell Co., Ltd..

Who is sponsoring NCT04594850?

NCT04594850 is sponsored by Pharmicell Co., Ltd..

What drugs are being tested in NCT04594850?

Interventions in NCT04594850: Cellgram-ED.

What condition does NCT04594850 study?

NCT04594850 studies Erectile Dysfunction.

Is NCT04594850 still recruiting?

NCT04594850 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT04594850: Cellgram-ED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously

Completed Phase 2 Last updated 9 February 2026

What this trial tests

Phase 2 trial testing Cellgram-ED in Erectile Dysfunction in 54 participants. Completed in 7 January 2026.

Timeline

19 October 2020

Primary endpoint
7 January 2026

7 January 2026

Quick facts

Lead sponsor	Pharmicell Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	54
Start date	19 October 2020
Primary completion	7 January 2026
Estimated completion	7 January 2026
Sites	4 locations across South Korea

Drugs / interventions tested

Cellgram-ED — full drug profile →

Conditions studied

Erectile Dysfunction — all drugs for Erectile Dysfunction →

Sponsor

Pharmicell Co., Ltd. — full company profile →

Who can join

Adults 19 to 79, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review.
Zhankina R, Baghban N, Askarov M, Saipiyeva D, et al · · 2021 · cited 49× · PMID 33823925 · DOI 10.1186/s13287-021-02295-9
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
Recent advances in stem cell therapy for erectile dysfunction: a narrative review.
Wang B, Gao W, Zheng MY, Lin G, et al · · 2023 · cited 10× · PMID 37078259 · DOI 10.1080/14712598.2023.2203811
Interrogating erectile dysfunction and evaluating novel therapeutic frontiers, with emphasis on stem cell strategies.
Sonawane T, Kashte S, Khera S, Bahulkar A, et al · · 2024 · cited 1× · PMID 39023828 · DOI 10.1007/s10815-024-03165-y
Mitochondrial transplantation-a novel therapeutic strategy for erectile dysfunction: a narrative review.
Wen C, Cheng Y, Chen Z, Zhang S, et al · · 2025 · PMID 41368241 · DOI 10.21037/tau-2025-531

Verify or expand the search:

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting

Other Pharmicell Co., Ltd. trials

Trials by the same sponsor.

NCT07431008 — Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction · recruiting
NCT07400458 — Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration · NA · recruiting
NCT05042206 — Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease · Phase 1 · completed
NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
NCT04615845 — Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04594850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pharmicell Co., Ltd.
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing